康乃德生物 CNTB 深 滬
等待開盤 09-17 09:30:00 美东时间
1.24
+0.070
+5.98%
華盛通- 最 高1.38
- 今 開1.14
- 成交量 340.61万股
- 最 低 1.13
- 昨 收 1.17
- 總市值 7808.81万
- 52周最高 3.82
- 市盈率 靜 --
- 換手率 5.41%
- 52周最低 1.061
- 委 比 2.08%
- 總股本 6297.43万
- 歷史最高 29.274
- 量 比 1.00
- 振 幅 21.37%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart. The clinical-stage biopharmaceutical company is testing the anti-interleukin-4-receptor alpha antibody as an add-on treatment f...
09-15 23:46
Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate at 28 Days by 66% and Improved Lung Function Vs. Placebo
Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced topline results from its global phase 2 study evaluating rademikibart, the...
09-15 19:09
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Connect Biopharma Holdings Limited announced that its management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 11:30 a.m. ET. The live webcast and a replay will be available on the company's website. Connect Biopharma focuses on developing treatments for asthma and COPD, advancing rademikibart, a next-generation antibody targeting IL-4Rα. The company has licensed rade...
09-03 20:05
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma Holdings Limited reported completing enrollment in Phase 2 Seabreeze STAT studies for asthma and COPD acute exacerbations, with topline results expected in September 2026. The company also initiated a Phase 2 IV study for rademikibart. Financially, cash reserves stood at $31.5 million, supporting operations for at least a year. License revenues were $2.8 million for the quarter and $2.9 million for the half-year, while R&D expen...
08-12 20:05
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
Oppenheimer Initiates Coverage On Connect Biopharma Hldgs with Outperform Rating, Announces Price Target of $8
Oppenheimer analyst Mazahir Alimohamed initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $8.
07-09 21:34
分析师解读医疗健康企业：CG Oncology, Inc.（CGON）、阿尔尼拉姆制药（ALNY）与Connect Biopharma Holdings（CNTB）
医疗保健领域释放乐观信号，3名分析师分别对CG肿瘤公司（CGON）、阿尔尼拉姆制药（ALNY）、康奈生物医药控股（CNTB）发布看好评级。 核心标的相关评级与市...
06-30 21:06
